PriceTargets.com logo

Jounce Therapeutics - JNCE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.88 As of 05/4/2023 09:00 PM ET
▼ -0.05 (-2.59%)
Get New Jounce Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNCE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Jounce Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.88.

This chart shows the closing price for JNCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Jounce Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2023Piper SandlerDowngradeOverweight ➝ NeutralLow
2/24/2023Sumitomo Mitsui Financial GroupReiterated RatingOutperform ➝ NeutralLow
2/23/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
1/3/2023Piper SandlerLower TargetOverweight$6.00 ➝ $5.00Low
11/10/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$16.00 ➝ $3.00Low
9/6/2022Piper SandlerLower Target$6.00Low
8/31/2022Raymond JamesLower TargetStrong-Buy$20.00 ➝ $16.00Low
8/30/2022Piper SandlerLower Target$9.00 ➝ $6.00Low
8/9/2022Robert W. BairdLower Target$5.00Low
8/5/2022HC WainwrightLower TargetBuy$15.00 ➝ $11.00Low
5/23/2022Piper SandlerLower TargetOverweight$17.00 ➝ $9.00Medium
5/11/2022Robert W. BairdDowngradeOutperform ➝ Neutral$15.00 ➝ $7.00High
5/6/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$15.00 ➝ $20.00High
3/16/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$17.00High
2/4/2022CowenUpgradeMarket Perform ➝ OutperformMedium
11/5/2021Roth CapitalReiterated RatingBuyLow
11/4/2021Raymond JamesBoost TargetOutperform$10.00 ➝ $15.00High
9/14/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$10.00High
8/5/2021Piper SandlerLower TargetOverweight$20.00 ➝ $17.00Low
3/15/2021Piper SandlerInitiated CoverageOverweight$20.00High
2/28/2021Robert W. BairdReiterated RatingBuyLow
2/26/2021HC WainwrightBoost TargetBuy$11.00 ➝ $15.00High
12/4/2020HC WainwrightReiterated RatingBuy$11.00High
11/10/2020Roth CapitalLower TargetBuy$28.00 ➝ $15.00High
11/2/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
9/18/2020Roth CapitalInitiated CoverageBuy$28.00Low
9/2/2020Raymond JamesReiterated RatingBuy$12.00Low
9/2/2020HC WainwrightBoost TargetBuy$8.00 ➝ $9.00Low
8/21/2020JPMorgan Chase & Co.Reiterated RatingSellLow
8/10/2020HC WainwrightReiterated RatingBuy$8.00High
5/7/2020HC WainwrightLower TargetBuy$10.00 ➝ $8.00High
3/25/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$11.00High
3/2/2020HC WainwrightLower TargetBuy$13.00 ➝ $10.00High
2/27/2020CowenReiterated RatingHoldLow
2/7/2020CowenReiterated RatingHoldHigh
11/12/2019CowenReiterated RatingHoldHigh
8/11/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Jounce Therapeutics logo
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $1.88
Low: $1.88
High: $1.93

50 Day Range

MA: $1.89
Low: $1.84
High: $1.94

52 Week Range

Now: $1.88
Low: $0.58
High: $5.87

Volume

11,600,600 shs

Average Volume

2,457,142 shs

Market Capitalization

$98.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Jounce Therapeutics?

The following Wall Street analysts have issued reports on Jounce Therapeutics in the last twelve months: StockNews.com.
View the latest analyst ratings for JNCE.

What is the current price target for Jounce Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Jounce Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Jounce Therapeutics in the next year.
View the latest price targets for JNCE.

What is the current consensus analyst rating for Jounce Therapeutics?

Jounce Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for JNCE.

What other companies compete with Jounce Therapeutics?

Other companies that are similar to Jounce Therapeutics include Vigil Neuroscience, Sangamo Therapeutics, bluebird bio, Outlook Therapeutics and AlloVir. Learn More about companies similar to Jounce Therapeutics.

How do I contact Jounce Therapeutics' investor relations team?

Jounce Therapeutics' physical mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-3840 and its investor relations email address is [email protected]. The official website for Jounce Therapeutics is www.jouncetx.com. Learn More about contacing Jounce Therapeutics investor relations.